Djeinam Touré
Biographic Data
| ID | 7015763 |
|---|---|
| NAME | Djeinam Touré |
| GIVEN NAMES | Djeinam |
| FAMILY NAME | Touré |
| SIGNATURE | TOURE D |
| AFFILIATIONS | Helen Keller International |
| ORCID | 0000-0002-8392-1168 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Integration of azithromycin mass administration to 1–11-month-old children into an existing health platform to reduce child mortality
BACKGROUND: Azithromycin mass drug administration (MDA) to ages 1-59 months can reduce childhood mortality; however, more evidence is needed to support targeting a narrower age range of 1-11 months. This trial assesses the efficacy of azithromycin MDA to 1-11-month-old children in reducing mortality in a real-world setting with integration of vitamin A delivery within the established Child Health Days platform in Burkina Faso. METHODS: Mortalite …
Covid-19 concerns among caregivers and vitamin A supplementation coverage among children aged 6–59 months in four countries in Western sub-Saharan Africa
Objective: To assess child vitamin A supplementation (VAS) coverage in 2019 and 2020 and explore key factors, including COVID-19 concerns, that influenced VAS status in four sub-Saharan African countries. Design: Data from eight representative household surveys were used to assess VAS coverage. Multivariable logistic regression models examined the effect of rural/urban residence, child sex and age, caregiver education, COVID-19 concern and househ…
No prominent works on this page.
Covid-19 concerns among caregivers and vitamin A supplementation coverage among children aged 6–59 months in four countries in Western sub-Saharan Africa
Objective: To assess child vitamin A supplementation (VAS) coverage in 2019 and 2020 and explore key factors, including COVID-19 concerns, that influenced VAS status in four sub-Saharan African countries. Design: Data from eight representative household surveys were used to assess VAS coverage. Multivariable logistic regression models examined the effect of rural/urban residence, child sex and age, caregiver education, COVID-19 concern and househ…
Integration of azithromycin mass administration to 1–11-month-old children into an existing health platform to reduce child mortality
BACKGROUND: Azithromycin mass drug administration (MDA) to ages 1-59 months can reduce childhood mortality; however, more evidence is needed to support targeting a narrower age range of 1-11 months. This trial assesses the efficacy of azithromycin MDA to 1-11-month-old children in reducing mortality in a real-world setting with integration of vitamin A delivery within the established Child Health Days platform in Burkina Faso. METHODS: Mortalite …
Child Nutrition and Water Access (2 works) · Global Maternal and Child Health (2 works) · Azithromycin (1 works) · Child health (1 works) · Cote d ivoire (1 works) · COVID-19 Impact on Reproduction (1 works) · Demography (1 works) · Demography (1 works) · Developing country (1 works) · Health services research (1 works)